RPRO TECHNOLOGY Trademark

Trademark Overview

On Friday, May 5, 2017, a trademark application was filed for RPRO TECHNOLOGY with the United States Patent and Trademark Office. The USPTO has given the RPRO TECHNOLOGY trademark a serial number of 79213572. The federal status of this trademark filing is REGISTERED as of Tuesday, December 3, 2019. This trademark is owned by LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES. The RPRO TECHNOLOGY trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Scientific and technological services, namely, laboratory research relating to the design of new pharmaceutical products and therapeutic protein-based medicines for others; design and development of new pharmaceutical products and therapeutic protein-based medicines for others utilizing recombinant DNA technologies; consulting services in the fields of pharmaceutical research and development, including therapeutic protein-based pharmaceutical research and development, and laboratory testing, diagnostics and pharmacogenetics related thereto; engineering; scientific laboratory services utilizing computer software platforms and recombinant DNA technologies for the development and optimization of pharmaceutical products, including therapeutic protein-based medicines, and laboratory analysis and laboratory research related thereto
rpro technology

General Information

Serial Number79213572
Word MarkRPRO TECHNOLOGY
Filing DateFriday, May 5, 2017
Status700 - REGISTERED
Status DateTuesday, December 3, 2019
Registration Number5923203
Registration DateTuesday, December 3, 2019
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 17, 2019

Trademark Statements

NOT AVAILABLE"TECHNOLOGY"
Goods and ServicesScientific and technological services, namely, laboratory research relating to the design of new pharmaceutical products and therapeutic protein-based medicines for others; design and development of new pharmaceutical products and therapeutic protein-based medicines for others utilizing recombinant DNA technologies; consulting services in the fields of pharmaceutical research and development, including therapeutic protein-based pharmaceutical research and development, and laboratory testing, diagnostics and pharmacogenetics related thereto; engineering; scientific laboratory services utilizing computer software platforms and recombinant DNA technologies for the development and optimization of pharmaceutical products, including therapeutic protein-based medicines, and laboratory analysis and laboratory research related thereto

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, August 4, 2017
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameLABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
Party Type30 - Original Registrant
Legal Entity Type33 - NOT AVAILABLE
AddressF-91940 LES ULIS
FR
Party NameLABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
Party Type20 - Owner at Publication
Legal Entity Type33 - NOT AVAILABLE
AddressF-91940 LES ULIS
FR
Party NameLABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
Party Type10 - Original Applicant
Legal Entity Type33 - NOT AVAILABLE
AddressF-91940 LES ULIS
FR

Trademark Events

Event DateEvent Description
Tuesday, August 8, 2017APPLICATION FILING RECEIPT MAILED
Thursday, August 3, 2017SN ASSIGNED FOR SECT 66A APPL FROM IB
Friday, August 4, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, August 4, 2017ASSIGNED TO EXAMINER
Tuesday, August 8, 2017NON-FINAL ACTION WRITTEN
Wednesday, August 9, 2017NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Thursday, August 10, 2017REFUSAL PROCESSED BY MPU
Thursday, August 10, 2017NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, August 25, 2017REFUSAL PROCESSED BY IB
Thursday, January 25, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, January 25, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, January 25, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, January 30, 2018SUSPENSION LETTER WRITTEN
Tuesday, January 30, 2018LETTER OF SUSPENSION E-MAILED
Tuesday, January 30, 2018NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Monday, July 30, 2018REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Wednesday, January 9, 2019NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Wednesday, January 9, 2019NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Friday, January 25, 2019NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Wednesday, January 30, 2019REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Thursday, August 1, 2019EXAMINER'S AMENDMENT ENTERED
Thursday, August 1, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, August 1, 2019EXAMINERS AMENDMENT -WRITTEN
Thursday, August 1, 2019EXAMINERS AMENDMENT E-MAILED
Thursday, August 1, 2019NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, August 9, 2019ASSIGNED TO LIE
Wednesday, August 28, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, August 28, 2019NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, August 28, 2019NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Tuesday, September 17, 2019PUBLISHED FOR OPPOSITION
Tuesday, September 17, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Thursday, September 19, 2019NOTIFICATION PROCESSED BY IB
Tuesday, December 3, 2019REGISTERED-PRINCIPAL REGISTER
Tuesday, March 3, 2020FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Saturday, March 21, 2020GENERIC MADRID TRANSACTION CREATED
Saturday, March 21, 2020GENERIC MADRID TRANSACTION SENT TO IB
Friday, March 5, 2021NEW REPRESENTATIVE AT IB RECEIVED
Saturday, April 3, 2021CORRECTION TRANSACTION RECEIVED FROM IB
Friday, April 9, 2021NEW REPRESENTATIVE AT IB RECEIVED
Saturday, May 4, 2024NEW REPRESENTATIVE AT IB RECEIVED
Tuesday, April 27, 2021CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Friday, May 29, 2020FINAL DECISION TRANSACTION PROCESSED BY IB

Related Keywords

technology rpro laboratory pharmaceutical therapeutic based protein research development products services medicines